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ABSTRACT 
Telomerase reverse transcriptase (TERT) is the catalytic component of telomerase, an RNA-
dependent DNA polymerase responsible for telomere elongation. TERT is transcriptionally repressed 
in most normal human somatic cells with limited life-span, which contributes to telomerase silence. It 
is well established that maintenance of telomere length is essential to cellular immortalization and 
malignant transformation, and predominantly achieved through TERT induction and subsequent 
telomerase activation. Evidence has also accumulated that, apart from its canonical telomere-
lengthening function, telomerase or TERT exhibits many other biological activities, thereby 
promoting cancer progression. Given its critical role in cancer formation and differential expression 
between normal and malignant cells, TERT/telomerase has been suggested as a novel cancer 
diagnostic marker and therapeutic target. To rationally develop these telomerase-based clinical 
applications, it is a demanding task to gain profound insights into the regulatory mechanism 
underlying cancer-specific TERT expression or telomerase activation, and to delineate various roles 
of TERT/telomerase in cancer development/progression. My thesis thus focuses on these important 
issues. Specifically, I sought to determine: (i) the biological role and clinical implication of the 
somatic TERT promoter mutation, and (ii) the regulatory effect of TERT on the oncogenic factor 
cyclooxygenase2 (COX2) in human cancer.  
The somatic TERT promoter mutation, initially identified in malignant melanoma, stimulates TERT 
gene transcription and activates telomerase. To see whether this genetic event occurs in the 
pathogenesis of thyroid and gastric cancer, we sequenced the TERT promoter region in tumor 
specimens derived from patients with premalignant thyroid lesions, thyroid and gastric cancer 
(papers I, II and III). A moderate to high frequency of TERT promoter mutations was observed in 
follicular cell-derived but not in parathyroid C cell-derived thyroid cancer. The mutation was 
correlated with senior age, shorter telomere length, aggressive disease and shorter disease-specific 
survival in thyroid cancer. Importantly, we found the mutation in a fraction (up to 17%) of 
premalignant thyroid lesions, coupled with TERT and telomerase expression, which indicates that 
TERT promoter mutations are early genetic events in thyroid carcinogenesis. In contrast, none of 
tumors from 200 patients with gastric cancer harbored TERT promoter mutations, suggesting 
different mechanisms for telomerase activation in gastric cancer. 
One of non-canonical TERT functions is to serve as a transcription co-factor to regulate gene 
expression. We thus determined whether the manipulating TERT expression affected the abundance 
of the oncogenic factor COX2 in cancer cells (paper IV). The inhibition of TERT in cancer cell lines 
using RNA interference led to a robust increase in COX2 expression at both mRNA and protein 
levels through a p38 MAPK signal pathway. TERT depletion alone did not affect cell survival, while 
the COX2 inhibitor together with TERT inhibition synergistically induced apoptosis of cancer cells. 
TERT depletion combined with the COX2 inhibitor administration significantly inhibited tumor 
growth in the mouse xenograft model of human gastric cancer. These findings reveal a novel function 
of TERT and have implications in telomerase-based anti-cancer therapy.  
In conclusion, the TERT promoter mutation is an early genetic event activating telomerase in the 
thyroid carcinogenesis, and associated with the aggressive disease and serves as a useful prognostic 
factor in thyroid cancer. The COX2 induction by TERT inhibition likely protects cancer cells from 
apoptosis. Thus simultaneously targeting TERT and COX2 may have synergistic killing effects on 
cancer cells, thereby improving treatment efficacy in a telomerase-based anti-cancer strategy.  
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1. INTRODUCTION 
1.1 Telomere 
1.1.1 Telomere structure 
Telomere is the structure at the end of linear chromosomes. In all eukaryotes, the 
chromosome ends with tandem guanine-rich repeats. The human telomere 
sequence is (TTAGGG)n repeats ranging from 8 to 20 kb, and is in dynamic 
homeostasis. [1] [2] [3] There is a 3’ overhang in telomere that usually loops 
back and inserts into the double strand of the telomere, thereby forming the t-
loop and making the chromosome more stable. [4]  
1.1.2 Telomere-binding proteins 
Telomeric DNA is associated with a specific protein complex, which is essential 
for maintaining the structure and functionality of telomere. The most important 
protein complex structure is shelterin, which includes TRF1 (TTAGGG-repeat 
binding factor 1), TRF2, TIN2, RAP2, TPP1 and POT1. TRF1 and TRF2 bind 
the double-stranded telomere and combine with the rest proteins to form a 
special structure at the end of chromosomes. Shelterin regulates 3’ overhang and 
t-loop formation. [5] 
1.1.3 Telomere shortening with cell division 
In most normal human cells, the telomere length is shortened with each cell 
division due to lack of telomere maintenance mechanism plus the end replication 
problem. When telomere is shortened to a certain limit, cells will stop divide and 
undergo permanent growth arrest so-called replication senescence. [6, 7] 
Therefore, most normal human cells are incapable of dividing indefinitely.  
1.1.4 Telomere function 
Telomere helps to maintain the stability and integrity of chromosomes. Telomere 
and their binding proteins form special structure at the end of chromosomes, 
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thereby protecting chromosomes from being recognized as double-stranded 
breaks or end-to-end fusion and suppressing DNA damage response. Telomere 
also prevents chromosome end degradation by excessive nuclease. Importantly, 
progressive telomere shortening occurs as cells divide, which serves as a mitotic 
clock to control cell life-span and to prevent unlimited cellular proliferation. 
 
1.2 Telomerase 
Telomerase is a ribonucleoprotein enzyme that synthesizes telomeric TTAGGG 
repeats at the end of linear eukaryotic chromosomes. Telomerase is a RNA-
dependent DNA polymerase that consists of a catalytic subunit telomerase 
reverse transcriptase (TERT), a RNA template TERC and many other 
components (Figure 1). [3, 8, 9] TERC is constitutively expressed in cells 
whereas TERT expression is tightly regulated in time, place and quantity, which 
makes TERT the rate-limiting subunit of telomerase. [10] [11] Normal cells stop 
divide at the hayflick-limit, but tumor cells need a telomere maintenance 
mechanism to evade the hayflick-limit or senescence. Telomerase activation is 
the major mechanism for maintaining telomere length in cancer cells. 
 
 
Figure1. The telomerase complex. It consists of a rate-limiting,
catalytic subunit TERT, an RNA template TERC, and other
components. TERT and TERC are the core of the telomerase complex
and sufficient to constitute telomerase activity.
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1.2.1 Telomerase activity and subunit expression in normal and cancer cells 
Telomerase is a huge ribonucleoprotein complex with the key components of 
TERT and TERC (Figure 1). [12] TERT and TERC are sufficient to constitute 
telomerase activity in vitro. In most differentiated human somatic cells, 
telomerase activity is undetectable or very low. [13-15] However, human 
germline cells have telomerase activity and thus maintain stable telomere length. 
Stem/progenitor cells, lymphocytes, and other cells with highly proliferative 
potentials express various levels of telomerase activity. [15-17] TERT 
expression is in general associated with acquisition of telomerase activity, and 
introduction of TERT into telomerase-deficient cells is sufficient to activate 
telomerase, suggesting a key role of TERT in controlling telomerase activity. [18]  
Telomerase activity is detectable in up to 90% of human malignant cells and the 
induction of TERT expression is a determinant step for acquisition of telomerase 
activity during cellular transformation as described above. [15, 17, 19] One of 
the key hallmarks of cancer is limitless replication potential, which is mainly 
achieved by TERT expression and telomerase activation. [20] Experimentally, 
TERT was shown to be one of essential elements for conversion of normal 
human cells into malignant ones. [19] Given the important role of TERT in 
cancer development, numerous efforts have been made to elucidate the 
mechanism governing TERT expression. [21, 22] 
 
1.2.2 The regulation of TERT expression 
The TERT gene was first cloned in 1997, [21] and since then, its regulation has 
been exclusively explored. TERT is regulated at multiple levels by numerous 
factors. [23-26] 
1.2.2.1 Genetic regulation of TERT expression 
Abnormal gene copy numbers. The TERT gene spans 40 kbs and is localized at 
chromosome 5p15.33. [25] Normal somatic cells from healthy individuals carry 
2 copies of the TERT gene, and loss or gain of the copy numbers causes 
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abnormities. In Cri du chat syndrome, patients were found to have one TERT 
allele deletion, coupled with lower telomerase activity in their cells. TERT is 
haploinsufficient for telomere maintenance in these patients. [27, 28] 
The gain of TERT gene copies occurs in human cancers, either from gain of 5p 
or gene amplification. Over 30% of human malignancies carry more than 3 
TERT copies, [29, 30] which contributes to telomerase activation in those 
malignancies. 
TERT gene mutations. The TERT gene point mutation has been found to result 
in many degenerative diseases, such as aplastic anemia, idiopathic pulmonary 
fibrosis and others. Non-synonymous TERT mutations cause stem cell 
dysfunction and lead to a low telomerase activity. [31, 32] In addition, the 
polymorphism or mutation at the regulatory region of the TERT gene also affects 
TERT expression and telomerase activity (See the TERT promoter mutation 
chapter below for details).  
1.2.2.2 Transcriptional regulation of TERT expression 
The TERT promoter is GC rich and lacks both TATA and CAAT boxes. It 
contains at least five Sp1 binding motifs, two E-boxes and a single transcription 
start site that binds multi-functional transcription factor TFII-I for gene 
expression. [33, 34] Numerous studies have shown that the TERT transcription 
machinery is controlled by various transcription and epigenetic factors (Figure 2). 
Positive transcription factors  
c-Myc 
The oncoprotein c-Myc is the well characterized transcription factor that 
activates TERT transcription. Myc forms a dimer with Max that binds to the 5′-
CACGTG-3′ consensus core sequence (E-box) in promoters, thereby trans-
activating target genes. [35] c-Myc is known to stimulate cell proliferation, block 
cellular differentiation, and promote tumorigenesis. Its role in trans-activation of 
the TERT gene is one of important driving-forces to transform cells. [36] 
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Sp1 family transcription factors 
The Sp1 transcription factor belongs to the Specificity Protein/Krüppel-like 
Factor (SP/KLF) transcription factor family and its consensus binding sequence 
is GGGGCGGGG or GGGTGGG. There are at least 5 Sp1 binding GC-boxes in 
the TERT core promoter region. [33] Sp1 cooperates with c-Myc to activate the 
TERT transcription, and when all the Sp1 binding sites are disrupted, the TERT 
promoter activity is erased, and even over-expression of c-Myc is unable to 
activate the promoter any longer. [37] 
Other positive regulators 
Apart from the above two major factors, many other positive factors regulate 
TERT transcription directly or indirectly. Survivin increases the DNA binding 
ability of c-Myc and Sp1, thus augmenting TERT transcription. [38] HPV E6 
oncoprotein forms a tertiary complex with E6AP and c-Myc, and binds to the E-
box, thereby increasing TERT transcription. STAT3, c-Jun, EWS-ETS and HIF-
1α have direct promoter interaction, stimulating TERT transcription. [39-43] 
Negative transcription factors 
Mad/Max heterodimer 
Mad is expressed in non-proliferating cells, inhibits proliferation, promotes 
differentiation, and prevents malignant transformation. Mad and Max forms a 
heterodimer that binds the same E-box as Myc/Max in the TERT core promoter, 
and competes with Myc/Max heterodimer binding to the promoter, thus 
repressing TERT expression. [29] During HL60 leukemic cell differentiation, 
there is a switch of E-box-binding from c-Myc/Max to Mad1/Max at the TERT 
promoter, and this switch is concomitant with shutting down of TERT 
transcription and silencing of telomerase. [29, 44] 
p53 
p53 is a negative regulator of TERT expression, which is compatible with its 
tumor suppressive role. p53 protein interacts with Sp1, a known TERT activator, 
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inhibiting Sp1 binding to the GC-box of the TERT promoter and repressing 
transcription. [45, 46] Expression of wild-type p53 in cancer cells causes 
decrease in TERT expression and telomerase activity, while tumor cells with 
mutant p53 have high-levels of telomerase activity. [45, 46] 
Other negative regulators 
Many tumor suppressors are also negative transcription regulators of TERT 
expression. Wilms’ tumor 1 (WT1) and menin can directly bind the promoter 
and repress TERT transcription. [44, 47] Rb, TGF-β/Smad and AP1 also 
contribute to TERT repression at the transcriptional level. [39, 44, 48, 49] 
1.2.2.3 Epigenetic regulation of TERT transcription 
The transcriptional regulation by above transcription factors is critical for TERT 
expression. However, there is an additional transcriptional controlling, the 
epigenetic mechanism, which also plays roles in regulating TERT expression. 
The epigenetic mechanism involves nucleosome/chromatin remodeling, DNA 
methylation and histone modifications. For example, histone 
acetylation/deacetylation is a common underlying feature to TERT 
transactivation/repression in human normal and malignant cells. [29] Histone 
methylation transferase SMYD3 is required for optimal stimulation of c-MYC 
and Sp1 on the TERT promoter, while histone demethylase RBP2, can interact 
with Mad1, and be recruited to the TERT promoter, thereby inhibiting TERT 
transcription. [50, 51] 
1.2.2.4 Post-transcriptional and post-translational regulation of TERT 
expression 
Alternative splicing of TERT mRNA is the key post-transcriptional mechanism 
in the regulation of TERT expression. At least five TERT mRNA variants have 
been identified in human cells but only the full-length transcript is capable of 
being translated into a catalytically active protein. [23, 52, 53] Post-translational 
regulation is involved in TERT protein modifications. Phosphorylated TERT 
protein has a longer half-life while its ubiquitination leads to a fast degradation. 
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1.2.3 Telomerase function independent of telomere-lengthening 
The canonical function of TERT is to maintain telomere length by synthesizing 
TTAGGG telomeric repeats at the end of chromosomes. Apart from its telomere 
lengthening function, TERT has many other activities in essential cellular 
processes, such as regulating gene expression, cell transformation, cell survival, 
mitochondrial function and epithelial-mesenchymal transition (EMT). [54] 
TERT can function as a transcriptional modulator. It occupies the Wnt target 
promoters, working as a cofactor in the Wnt-β-catenin transcriptional complex 
and regulating Wnt target gene expression. [55] The RNA component of 
mitochondrial RNA-processing endoribonuclease (RMRP) is a small non-coding 
RNA found in mitochondrial. TERT has been shown to interact with RMRP and 
functions as RNA-dependent RNA polymerase that produces double-stranded 
RNAs. These RNAs are further processed into small-interfering RNAs and 
regulate gene expression in a post-transcriptional way. [56] TERT also binds to 
Figure 2. Structure and regulation of the TERT promoter. Proteins 
that activate TERT are located above the line; repressors are located 
below the line. 
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the p65 subunit of NF-κB and promotes the expression of NF-κB target genes, 
including interlukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). [57] EMT is 
an important player in cancer metastasis. Ectopic TERT expression promotes 
whereas its inhibition attenuates EMT in cancer cells. [58] 
 
1.3 TERT promoter mutations 
Telomerase activation and TERT expression are important in cell 
immortalization and tumor progression. Although the regulation of TERT 
transcription has been extensively explored, the underlying mechanisms are still 
incompletely understood. More recently, TERT promoter mutations have been 
identified as important genetic events activating telomerase in different types of 
cancer.  
1.3.1 TERT promoter mutations - overview 
Gene mutations are frequently related with tumorigenesis, and the cancer-
specific mutations occur mostly in the protein-coding area, while rarely in the 
gene regulatory area. Recently, however, somatic TERT promoter mutations 
have been observed, which are located within 200 base pairs (bp) upstream of 
the ATG translation start site, and these mutations stimulate the TERT 
transcription by creating de novo ETS binding motifs. [59-61] 
TERT promoter mutations and their functional implication 
The TERT promoter mutations were first reported by Huang, et al and Horn, et 
al in 2013. [59-62] Both groups identified recurrent somatic mutations in the 
TERT promoter region in malignant melanoma. Two major mutations, which 
caused a cytidine-to-thymidine (C >T) dipyrimidine transition, localized at -
124 and -146 bp (chromosome 5 1,295,228 and 1,295,250) from the translation 
start site, and are named C228T and C250T, respectively (Figure 3). The two 
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mutations are found to be mutually exclusive. [59-61] The mutations exhibited 
the signature of an ultraviolet-induced DNA damage, and were found to be 
more frequent in sun-exposed sites in primary cutaneous melanoma. [59-61, 
63]     
The above mutations in the TERT promoter region have functional 
implications. Both C228T and C250T create a new sequence 5′-
CCCCTTCCGGG-3′, which is the E-twenty-six (ETS) transcription factor 
binding motif (GGAA, from the reverse strand) (Figure 3). Huang, et al 
constructed a TERT promoter luciferase reporter, and observed that the mutant 
TERT promoter activity increased by two to four fold compared with the wild-
type one in same cancer cells. [59-61] 
 
 
 
 
 
 
 
 
 
 
Figure 3. The structure of TERT promoter and the position of the two 
mutations: C228T and C250T. The mutation site is indicated above. C>T 
mutations leads to the generation of de novo ETS1 binding sites in the 
TERT proximal promoter region, thereby promoting TERT transcription. 
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In addition to these two major TERT promoter mutations, other mutations are 
also identified in that region. CC>TT tandem mutations at position -124/-
125bp and -138/-139, and C>T mutations at position -57 are found in a small 
proportion of cancer. [62] The two tandem mutations also contributed to the 
generation of an extra ETS transcription factor-binding motif. Moreover, the 
mutation at position -57 creates a CCGGAA ternary complex factor (TCF) 
binding site, which also enhances TERT transcription. [62]  
 
1.3.2 TERT promoter mutations in human cancer 
TERT promoter mutations are present in a vast type of cancers with different 
frequency and correlated with clinical variables. They are the most frequent 
mutation in hepatocellular carcinoma, bladder cancer and malignant melanoma. 
[59-61, 64-66] By contrast, no TERT promoter mutations were found in tumors 
such as breast and prostate cancer, leukemia, etc. [59-61, 67, 68] Details of 
TERT promoter mutations in human cancer are summarized in Table 1. 
Malignant melanoma was shown to express significantly higher levels of 
TERT mRNA in mutation-positive tumors than in negative ones. [59-61] 
Consistent with these observations, tumors from thyroid cancer, liver cancer 
and primary gliomas also exhibited higher TERT mRNA expression in the 
mutation-positive tumors. [66, 67, 69, 70] However, in bladder cancer, such an 
association was not seen. [65] 
Table 1. A Summary of TERT promoter mutations in cancer  
Tumor type Mutation frequency (%) References 
Urinary system   
Bladder cancer 55.6 - 85 [61, 64, 65, 68, 71-74] 
Renal cell carcinoma (RCC) 8.3 [71] 
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Clear cell RCC (ccRCC)  9.3 [75] 
Chromophobe RCC 13 [75] 
Upper Tract Urothelial Carcinomas (UTUCs) 47.3 [68] 
Renal pelvic cancer 60 - 63.7 [71, 75] 
Ureter cancer  11 [75] 
Digestive System   
Hepatocellular carcinoma (HCC)  44 - 59 [76] 
HCC borderline lesions 17 [76] 
Cirrhotic preneoplastic macronodules 25 [66] 
Primary gastric cancer 0 - 0.7 [77]  
Esophageal adenocarcinoma 0 [78] 
Esophageal squamous cell carcinomas 1.60 [79] 
Laryngeal cancer 0 [80] 
Gallbladder cancer 0 - 9.1 [81] 
Central nervous system   
Glioma 49 - 55 [82] 
Glioblastomas 54 - 84  [83-85]  
Medulloblastomas (MB) 21.0 [71] 
MBSHH  34 - 83 [71, 86] 
MBWNT 31 [60, 71] 
MBGroup3 <5  [60, 71] 
MBGroup4 <5  [60, 71] 
Meningiomas 28 [87] 
Gliosarcomas 81 [71] 
Solitary fibrous tumors 13 - 50 [71] 
Oligodendrogliomas  78 - 74 [84] 
Oligoastrocytomas 58 [84] 
Diffuse astrocytomas 19 [69] 
Anaplastic astrocytomas 25 [69] 
Malignant peripheral nerve sheath tumors 6 [88] 
Skin tumor   
Melanoma 22 - 71 [59-63, 89, 90] 
Acral lentiginous melanomas 6 [91] 
Non-acral cutaneous melanomas 33 [91] 
Uveal melanomas 0 [92] 
Conjunctival melanomas 32 [92] 
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Basal cell carcinomas (BCCs) 56 - 78 [93, 94] 
BCCs from X-irradiated patients  27 [89] 
BCCs from nonirradiated patients 51 [89] 
Primary melanocytic tumors 0 [95] 
Cutaneous squamous cell carcinomas 50 [93, 94] 
Atypical fibroxanthomas 93 [96] 
Pleomorphic dermal sarcomas 76 [96] 
Endocrine system   
Thyroid tumor   
Papillary thyroid carcinoma (PTC) 7.5 - 25 [70, 97-99] 
Follicular thyroid carcinoma (FTC) 13.9 - 36.4 [70, 97, 98, 100] 
Poorly differentiated carcinomas (PDTC) 29 [97, 98] 
Anaplastic thyroid carcinomas (ATC) 33.3 - 50 [70, 97, 98] 
Medullary thyroid carcinoma (MTC) 0 [70] 
Adrenal neoplasms 4.8 [61] 
Reproductive system   
Ovarian clear cell carcinomas  15.9% [101] 
Other tumors   
Malignant pleural mesothelioma 15 [73] 
Myxoid liposarcomas 74 - 79 [68, 88] 
Synovial sarcomas 0.4 [68, 88] 
Osteosarcomas  4.3 [68] 
Oral cavity cancers 17 [68] 
Cell lines   
Gastric cancer cell lines 0 [81] 
MTC cell lines 0 [70] 
ATC cell lines 75 [70] 
Bladder cancer cell lines 88 [74] 
Melanoma cell lines 0.74 [62] 
 
The TERT promoter mutation tends to be related to aggressive forms of 
malignancies. In thyroid carcinomas, anaplastic thyroid carcinoma (ATC), the 
most aggressive one, has the highest mutation rate (50%), while the 
differentiated thyroid carcinomas have a mutation rate 22 - 27%. [70] In renal 
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cell carcinoma, the mutation is also correlated with an advanced clinical stage 
(stage III/IV) and metastatic disease. [75] In primary glioblastoma and thyroid 
carcinomas, the mutation predicts a shorter patient survival. [68] 
The TERT promoter mutation is the most frequently observed genetic event in 
bladder cancer. The presence of the mutant TERT promoter in voided urine has 
been suggested to be a marker for bladder cancer diagnosis and recurrence. 
[65] However, the mutations detected in the urine could also come from other 
urological malignancies. In the analysis of upper tract urinary carcinoma, a 
renal pelvic carcinoma patient was also found to have a TERT promoter 
mutation in his urine sample. [75] When the mutant TERT promoter is detected 
in voided urine, differential diagnosis must be made between bladder cancer 
and other urological malignancies. 
The TERT promoter mutation frequency varies substantially from cancer to 
cancer. Killela et al hypothesized that it occurred mainly in tissues with low 
self-renewal rate and was mutually exclusive with the alternative lengthening 
of telomere. [68] However, more and more recent studies have suggested that 
malignancies with a high self-renewal may also acquire TERT promoter 
mutations. It is currently unclear what causes such differences in the mutation 
frequency among different malignancies.   
In summary, the detection of the mutant TERT promoter as a diagnostic 
marker seems promising. This marker has also been tested to distinguish 
benign tumors from malignancies and to judge the tumor origins, because of its 
specific mutation profile in different tumor types. Patients with thyroid cancer 
carrying the mutation tended to have a poor outcome, thus making the TERT 
promoter mutation a prognostic factor. Several strategies based on telomerase 
inhibition have entered into clinical trials. [102] Whether the detection of the 
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TERT promoter mutation will contribute to a better-individualized telomerase-
based therapy is worthy of exploring.  
 
1.4 Thyroid cancer 
The thyroid gland is the largest endocrine organ. It is located under the thyroid 
cartilage, and anterior to the larynx and trachea. The thyroid gland consists of 
two lobes with joint by isthmus, and a pyramidal lobe. Histologically, the basic 
unit of thyroid gland is the thyroid follicle, which is composed of epithelial 
follicular cells. Follicular cells constitute 90% of thyroid cells, and are 
responsible for secreting thyroid hormones. The remaining 10% of thyroid cells 
are called parathyroid cells or C-cells, which have a different histological origin 
and secret another hormone calcitonin. [103] 
 
 
   
  
 
  
 
 
The incidence of thyroid cancer is growing in the past decades although the 
death rate is low. [104] According to its histological constitution, thyroid cancer 
has two origins: the follicular cell-derived tumors, which consist of follicular 
thyroid adenoma (FTA), follicular thyroid carcinoma (FTC), papillary thyroid 
a 
Figure 4: (a) The anatomy position of thyroid gland. (b) The subtypes of thyroid 
carcinomas. 
b 
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carcinoma (PTC), anaplastic thyroid carcinomas (ATC), and the parathyroid 
cell-derived tumor, medullary thyroid carcinoma (MTC). [104]  
1.4.1 FTA: Follicular thyroid adenoma  
FTA is a benign thyroid tumor, which accounts for 3 - 4% of all thyroid tumors. 
FTA is surrounded by an entire thin fibrous capsule, and is distinguishable from 
its malignant form, FTC, based on cytology or clinical features. No invasion of 
capsule or vascular could be the definition of FTA. [105] AFTA is anaplastic 
FTA with uncertain malignancy.  
Although a benign tumor, certain genetic alterations occur in FTA. Oncogenic 
HRAS/NRAS mutations are found in 20 - 25% FTA. As an activator of the 
MAPK and PI3K–AKT pathways, the presence of RAS mutations indicates 
oncogenic alterations in those benign thyroid tumors. Moreover, a transition 
from FTA to FTC has been observed, and thus FTA is a pre-malignant lesion of 
the thyroid. [104] 
1.4.2 FTC: Follicular thyroid carcinoma  
FTC is a differentiated thyroid cancer, which accounts for approximately 15% of 
thyroid malignancies. FTC usually has thick and irregular capsule, and necrosis 
and mitosis occur frequently. Capsule or vascular invasion is a key feature 
distinguishing FTC from FTA. [105] 
The paired box 8 (PAX8) peroxisome proliferator-activated receptor-γ (PPARG) 
fusion gene (PAX8–PPARG) is the predominant genetic alteration in FTC. NRAS 
mutations and PTEN mutations or deletions are also oncogenic drivers in FTC 
pathogenesis. [104] 
1.4.3 PTC: Papillary thyroid carcinoma  
PTC is the most common thyroid cancer and constitutes 80 - 85% of all thyroid 
cancers. [104] It has a good prognosis and the 10-year survival rate is over 80%. 
PTC is also a differentiated cancer. It has papillary architecture and special 
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characteristic nuclear features like enlargement, elongation, etc., which 
distinguish PTC from other follicular cell-derived thyroid cancer. [104]  
The BRAF gene T1799A point mutation, which generates BRAF V600E mutant 
protein, is the most common genetic alteration in PTC. BRAFV600E is found in 30 
- 70% PTCs. The mutant protein is required for tumor growth and responsible 
for PTC pathogenesis. BRAF mutations in general predict poor patient outcomes. 
[104] 
1.4.4 ATC: Anaplastic thyroid carcinoma  
ATC is undifferentiated thyroid cancer. It is the least common while the most 
aggressive type of thyroid cancer. It accounts for 2 - 3% of all thyroid cancers. 
[104] ATC patients have a poor prognosis. According to a survey in USA, the 
patients’ median survival was 5 months, and one-year survival is only 20%. 
[106] ATC may come from a differentiated thyroid cancer or occur as a de novo 
disease. 
ATC has multiple genetic abnormalities. They include mutations in TP53, 
CTNNB1, BRAF, RAS, PTEN, and other genes, making ATC the most malignant 
thyroid cancer. 
1.4.5 MTC: Medullary thyroid carcinoma 
MTC is the only malignancy that arises from parafollicular or C-cells and 
accounts for 5 - 8% of all thyroid cancers. The proto-oncogene RET mutation is 
considered to be the major genetic alteration in MTC and a negative prognostic 
factor. Mutations related with follicular cell-derived carcinomas, such as BRAF 
and RAS mutations, are not found in MTC. [107] 
 
1.5 Gastric cancer 
1.5.1 Overview 
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Gastric cancer is the fourth most-common cancer in the world. It’s on the second 
place of cancer mortality, just after lung cancer. The incidence of gastric cancer 
has declined in the past decades in developed countries, but in most developing 
countries, like China, the incidence is still high, which leads to heavy social 
burdens. [108] In 2004, 264,000 patients were diagnosed with gastric cancer, and 
206,000 patients died in China. Over 90% of gastric cancer are adenocarcinoma 
and mainly divided into two histologic subtypes: intestinal and diffuse. [108] 
Helicobacter pylori, an infectious agent, have been recognized to be strongly 
associated with gastric cancer development. H. pylori was classified as class I 
carcinogen by the International Agency for Research on Cancer (IARC) in 1994. 
[108] Epstein-Barr Virus (EBV), an oncogenic virus, is also related to the 
pathogenesis of gastric cancer. 
A precancerous to cancerous cascade is well defined in gastric cancer: normal→ 
chronic nonatrophic gastritis → atrophic gastritis → gastric cancer. Gastric 
cancer has poor outcomes in general. 
1.5.2 The role of cyclooxygenae-2 (COX2) in cancer 
Cyclooxygenase-2 is also called Prostaglandin-endoperoxide synthase 2. It is 
the rate-limiting enzyme for the conversion of arachidonic acid into 
prostaglandin H2. There are two isoforms of cyclooxygenase: COX1, 
constitutively expressed in most tissues, and COX2, unexpressed under normal 
conditions in most cells, while induced during inflammation. COX2 is also an 
oncogenic factor; it promotes angiogenesis, induces tumor cell growth, inhibits 
apoptosis and attenuates immune-surveillance function. [109-113] 
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2. AIMS OF THE STUDY 
The overall objective of the present study is to delineate regulatory mechanisms 
underlying cancer-specific TERT expression, novel roles of TERT/telomerase in 
cancer development/progression, and their clinical relevance. Specifically, the 
study is aimed at 
1. determining TERT promoter mutations in thyroid and gastric cancer. 
2. defining the relationship between TERT promoter mutation and clinical 
variables in thyroid carcinomas. 
3. defining novel functions of TERT in oncogenesis for rational development of 
telomerase-based anti-cancer strategies. 
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3. MATERIALS AND METHODS 
3.1 Human patient samples 
3.1.1 Thyroid carcinoma/ adenoma tissues (Paper I and II) 
We collected tissue samples from 144 patients with thyroid cancers who were 
diagnosed and underwent surgery at Karolinska University Hospital Solna. The 
patients included 20 ATCs, 51 PTCs, 52 FTCs and 37 MTCs. We also collected 
58 FTAs and 18 AFTAs tumor specimens from 76 patients at the same hospital. 
The specimens were collected after surgical treatment within Karolinska 
University Hospital and kept frozen at -70 oC until use. Tumors were diagnosed 
according to the criteria of the World Health Organization. All samples were 
collected with informed consent and approved by the local ethics committee. 
Detailed clinical information of patients is given in Supplementary Tables S1-S3 
in paper I and paper II. 
3.1.2 Gastric cancer tissues (Paper III) 
Tumor tissues from two hundred patients with gastric cancer were collected from 
Qilu hospital, Shandong, China. Formalin-fixed paraffin embedded tumor tissues 
were used. The study was approved by the local ethics committee. Tumors were 
diagnosed according to the criteria of the World Health Organization. 
3. 2 Established human cell lines 
3.2.1 Thyroid cancer cell lines (Paper I) 
We used 10 human thyroid cancer cell lines in the study (Table 2), and they were 
C643W, SW1736, U-hth7, U-hth74, U-hth112, U-hth104, ARO and KAT-4, 
[114] MTC-TT (ATCC) and MZ-CRC-1 (provided by Dr. BG.Robinson at 
University of Sydney). 
3.2.2 Gastric cancer and other cell lines (Paper IV) 
Human gastric cancer cell line AGS and cervical cancer cell line HeLa were 
from American Type Culture Collection (ATCC) (Table 2). The gastric cancer 
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cell line BGC-823 was bought from Beijing Cancer Institute, China in 2008. 
Normal human fibroblasts were from Life Technology and the Osteosarcoma 
cell line U2OS was a gift from professor Yusheng Cong, Hangzhou Normal 
University, China (Table 2). 
Table 2. Cell lines used in this thesis. 
Name Origin Subtype Paper 
C643W Thyroid cancer ATC I 
SW1736 Thyroid cancer ATC I 
U-hth7 Thyroid cancer ATC I 
U-hth74 Thyroid cancer ATC I 
U-hth12 Thyroid cancer ATC I 
U-hth104 Thyroid cancer ATC I 
ARO Thyroid cancer ATC I 
KAT-4 Thyroid cancer ATC I 
MZ-CRC-1 Thyroid cancer MTC I 
MTC-TT Thyroid cancer MTC I 
AGS Gastric cancer  IV 
BGC-823 Gastric cancer  IV 
HeLa Cervical cancer  IV 
U2OS Osteosarcoma  IV 
Normal human skin fibroblasts Normal cells  IV 
 
3.3 DNA extraction and Sanger sequencing (Paper I, II and III) 
In the present study, genomic DNA was extracted from frozen tumor tissue 
samples using standard methods and from paraffin tissues using a DNA FFPE 
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Tissue Kit (QIAGEN). The genomic DNA was then applied with the primers 
spanning the hTERT promoter, BRAF, HRAS, KRAS and NRAS genes using a 
QIAGEN Hotstar DNA polymerase. PCR was performed based on the 
manufacture’s instruction and primers sequences are listed in Table 3.  
The TERT promoter region is GC-rich and is difficult to amplify using 
conventional PCR conditions. We solved this problem by adding betaine in the 
reaction mixture. Betaine is a chemical compound that increases PCR 
amplification efficiency by reducing the formation of secondary structure in the 
GC-rich DNA region. [115]  
Sanger sequencing was developed in 1975 by Sanger as the first generation 
sequencing technology based on four-color fluorescence and automated capillary 
electrophoresis (CE) systems. [116] It is the conventional method to analyze 
DNA sequences. Both deoxy-ribonucleoside triphosphate (dNTPs) and dideoxy-
ribonucleoside triphosphate (ddNTps) are added into PCR reaction systems. The 
ddNTPs, which may be radioactively or fluorescently labeled for detection, lack 
the 3’-OH and cannot be amplified. dNTPs and ddNTPs bind to the template 
randomly. The PCR reaction will cease when ddNTPs bind to the template, 
which generate different sized PCR fragments. These fragments can be separated 
by size using gel electrophoresis and different termination signals can be 
detected and analyzed to get the template sequence.  
After PCR reaction, products were purified and precipitated with ethanol and 
EDTA. The Sanger sequencing was conducted with BigDye Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems) in an ABI 3730 DNA analyzer 
machine. We used CodonCode Aligner software to analyze the sequencing 
results and the mutation samples were confirmed from both directions. 
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Table 3. Primers used for PCR and Sanger sequencing in this thesis. 
Purpose / Target Description      Sequence
Sequencing of TERT   
TERT promoter Forward 5’ - CACCCGTCCTGCCCCTTCACCTT - 3’ 
TERT promoter Reverse 5’ - GGCTTCCCACGTGCGCAGCAGGA - 3’ 
Sequencing of HRAS   
HRAS exon 1 codon 
12/13 
Forward 5’ - ATGACGGAATATAAGCTGGT - 3’  
HRAS exon 1 codon 
12/13 
Reverse 5’ - CTCTATAGTGGGGTCGTATT - 3’ 
HRAS exon 2 codon 61 Forward 5’ - AGGTGGTCATTGATGGGGAG - 3’ 
HRAS exon 2 codon 61 Reverse 5’ - AGGAAGCCCTCCCCGGTGCG - 3' 
Sequencing of KRAS   
KRAS exon 1 codon 
12/13 
Forward 5’ - GGCCTGCTGAAAATGACTGAA - 3’  
KRAS exon 1 codon 
12/13 
Reverse 5’ - GGTCCTGCACCAGTAATATGC - 3’ 
KRAS exon 2 codon 61 Forward 5’ - CAGGATTCCTACAGGAAGCAAGTAG - 3' 
KRAS exon 2 codon 61 Reverse 5’ - CACAAAGAAAGCCCTCCCCA - 3’ 
Sequencing of NRAS   
NRAS exon 1 codon 
12/13 
Forward 5’ - ATGACTGAGTACAAACTGGT - 3’ 
NRAS exon 1 codon 
12/13 
Reverse 5’ - CTCTATGGTGGGATCATATT - 3’ 
NRAS exon 2 codon 61 Forward 5’ - TCTTACAGAAAACAAGTGGT - 3’ 
NRAS exon 2 codon 61 Reverse 5’ - GTAGAGGTTAATATCCGCAA - 3’ 
 
3.4 Telomere length assessment (Paper I, II and IV) 
3.4.1 Quantitative PCR (qPCR) 
We used two methods to measure telomere length. In paper I and II, a well-
established qPCR method was used to determine telomere length from frozen 
tissues. [117] TEL primers were specially designed to amplify telomere (T) 
repeats and beta-globin (HBG) was used as a standard (S) reference gene. 
 23 
 
Relative telomere length was determined by calculating T/S values using the 
formula, T/S=2-ΔCt, where ΔCt=average Cttelomere －average Ctβ-globin.  
3.4.2 Q-FISH  
Quantitative Fluorescent in situ Hybridization (Q-FISH) is a more informative 
method to measure telomere length. It provides visible and individual telomere 
length assessment with the resolution to 200 bps. [118] Cells are fixed with 4% 
paraformamide and incubated with fluorescence-labeled PNA (CCCTAA) 3’ 
probe. The signal intensity in 50 cells was determined using NIS software 
(Nikon, Stockholm, Sweden) and expressed in arbitrary units. 
 
3.5 RNA extraction, reverse transcription and qPCR 
 
To detect gene mRNA expression in different cells or tissues, we used qPCR. 
Total RNA was extracted using Trizol method (Invitrogen). RNA was then used 
as the template to synthesize cDNA with random primers (N6, Amersham, 
Buckinghamshire, UK) and M-MLV reverse transcriptase (Invitrogen). qPCR 
was carried out in an ABI7900HT fast real-time system (Applied Biosystems) 
using SYBR green master mix kit (Applied Biosystems). The primers used in the 
study are listed in Table 4. We used β-2 microglobulin (β-2M) as the internal 
control and 2-ΔΔCt method was used to calculate relative mRNA expression. [119] 
 
Table 4. Primers used for qPCR determination of gene expression  
Target Description Sequence 
TERT Forward 5’-CGGAAGAGTGTCTGGAGCAA-3’ 
 Reverse 5’-GGATGAAGCGGAGTCTGGA-3’ 
COX2 Forward 5’-GCCCAGCACTTCACGCATCAG-3’ 
 Reverse 5’AGACCAGGCACCAGACCAAAGACC-3’ 
COX1 Forward 5’-CGGCTGCAGCCCTTCAATGAGT-3’ 
 Reverse 5’-CTCTCCCCAAAGATAGAGTTTGGA-3’ 
β2-M Forward 5’-GAATTGCTATGTGTCT GGGT-3’ 
 Reverse 5’-CATCTTCAAACCTCCATGATG-3’ 
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3.6 Telomerase activity measurement (Paper II and IV) 
We used a commercial Telomerase PCR ELISA kit (Roche Diagnostics 
Scandinavia AB, Stockholm, Sweden) to detect telomerase activity. For each 
assay, 1 µg of protein was used, and 26 PCR cycles were performed after the 
telomerase-primer elongation reaction. The PCR products were detected using 
ELISA color reaction and the level of telomerase activity was expressed as 
absorbance in arbitrary units. 
 
3.7 COX2 promoter activity assay (Paper IV) 
The COX2 reporter plasmid contains the core promoter sequence (-327/+59) 
inserted into a luciferase-encoding DNA fragment and its luciferase activity 
indicates the transcriptional level of the COX2 gene. [120] The plasmid was 
transfected into the treated or control BGC cells, and the COX2 promoter-driven 
luciferase activity was then determined using a dual luciferase reporter assay 
system (Promega, Madison, WI, USA) 48 hrs post transfection, and the target 
promoter-driven firefly luciferase activity was normalized to the renilla activity 
included in the kit. 
 
3.8 Western blot (Paper IV) 
Western blot or protein immunoblot is widely used to detect proteins from 
cells/tissues. Total cellular proteins were extracted using RIPA lysis buffer, and 
the concentration of proteins was measured using a BCA method. For the 
assessment of phosphorylated p38 MAPK, sodium orthovanadate was added to 
lysis and washing buffers to inhibit phosphatases. Proteins were then denatured 
at 100 oC for 5 minutes. Twenty microgram of proteins were subjected to SDS-
polyacrylamide gel electrophoresis and transferred to a PVDF membrane. The 
membrane was then incubated with specific antibodies against COX2 (Cayman 
chemical, Ann Arbor, MI, USA), Phospho-p38 MAPK (Thr180/Tyr182), p38 
MAPK (Cell Signaling Technology, Billerica, MA, USA) or β-actin (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) and then with secondary anti-mouse or 
rabbit horseradish peroxidase-conjugated IgG (Bio-Rad, Hercules, CA, USA), 
and finally developed with the chemiluminescence method (ECL, Amersham, 
Little Chalfont, UK). 
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3.9 Flow cytometry (Paper IV) 
Flow cytometry (FCM) is a laser based, biophysical technology employed, and 
multi-parameter biotechnology. FCM is widely used in cell counting, apoptosis 
and cell cycle analysis, cell sorting and biomarker detection, etc.. The amount of 
chromatins varies in different cell phases. S-phase cells have double amounts of 
chromatin comparing to G0/1-phase cells, and apoptotic cells have chromatin 
breakages. Propidium iodide (PI) is a fluorescent molecule that can bind to 
nucleic acid. Cells were fixed with ethanol and stained with PI, and the 
fluorescent signal shows the different DNA contents in each cell phase, which 
helps to define cell cycle distribution and to differentiate necrotic and apoptotic 
cells from living ones.  
In our experiments, cells are fixed with 70% ethanol at 4 oC overnight and 
stained with RNAse A (0.5 mg)-containing PI (50 µg/ml). Cell cycle distribution 
and apoptosis were determined using flow cytometry with ModFit (BD 
Biosciences, Franklin Lakes, NJ, USA).  
 
3.10 Cell culture and TERT gene knock down (Paper IV) 
 
Human gastric cancer cell lines and cervical cancer cell line were cultured in 
RPMI-1640 medium with 10% Fetal Bovine Serum (FBS) and L-glutamine in a 
37oC, 5% CO2 incubator.  
 
3.10.1 Small-interfering RNA (siRNA)  
siRNA is a class of 20-25 base pairs in length, double-stranded RNA molecules. 
Each siRNA is unwound into two single-stranded (ss) ssRNAs, the passenger 
strand and guide strand. The passenger strand is degraded whereas the guide 
strand is incorporated into the RNA-induced silencing complex (RISC), which 
causes the transcriptional silence of complementary message RNA (mRNA). 
siRNA is a widely used tool in transcriptional silencing. In our study, we bought 
chemical modified Stealth control (5’-
CCUACAUCCCGAUCGAUGAUGUUGA-3’) and TERT (5’-
AGGCACUGUUCAGCGUGCUCAACUA-3’) siRNAs from Invitrogen. The 
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siRNAs were transfected into cells using lipofectamine 2000 (Invitrogen) 
according to the manufacture’s instruction.  
 
3.10.2 Lenti-viral vector construction 
The gene knock down by siRNAs is transient. In order to stably inhibit TERT 
expression, we infected cells with a lenti-viral vector encoding TERT siRNA 
(Invitrogen).  
Lentivirus belongs to the retrovirus family. It delivers viral RNA into host cells 
and infects both dividing and non-dividing cells. We used the second-generation 
packaging system, which include the packaging plasmid psPAX2 and envelop 
plasmid pMD2. G (Addgene). The TERT siRNA psPAX2 and pMD2.G were 
transfected into 293FT virus package cells. Supernatant was collected 24 hrs and 
48 hrs post-transfection. The virus-containing medium was then centrifuged and 
concentrated. Cells are selected with 2 µg/ml puromycin 48 hrs after infection. 
 
3.11 Mouse model (Paper IV) 
The mouse model maximally mimics the in vivo biological progress without the 
added risk of harming actual human. In our study, we used a mouse model to 
investigate the synergistic anti-cancer efficacy by targeting both TERT and 
COX2. 
 
BGC-823 cells infected with control and siTERT lenti-viral vectors were 
harvested, and 2×106 cells were suspended in 100 µl PBS. The cells were then 
subcutaneously injected into nude mice (Shanghai Slac Laboratory Animal Co. 
Ltd., Shanghai, China) at the right back. The experiments were carried out with 
the university ethics committee approval and met the standards required by the 
UKCCCR guidelines. [121] Mice were killed after 3 weeks and tumors were 
collected for the measurement of weight, size and other analyses. 
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4. RESULTS 
4.1 TERT promoter mutations in cancer and their clinical implication 
4.1.1 The frequency of TERT promoter mutations in cancer 
In this thesis, we sequenced the TERT promoter in different tumors, including 
thyroid carcinoma, benign thyroid tumor and gastric cancer. The frequency of 
TERT promoter mutation was different in these tumors and cancer subtypes 
(Table 5). 
Table 5. Summary of TERT promoter mutations detected in thyroid and gastric tumors 
Number  Mutated  Wild-type 
Tumor type Investigated Number  Number 
Thyroid tissue samples 
Anaplastic thyroid carcinoma (ATC)  20  10 / 20 (50%)  10 / 20  
Papillary thyroid carcinoma (PTC) 51  13 / 51 (27%)  38 / 51  
Follicular thyroid carcinoma (FTC) 36  8 / 36 (22%)  28 / 36  
Medullary thyroid carcinoma (MTC) 37  0 / 37 (-)  37 / 37 
Follicular thyroid adenoma (FTA) 58 1/58 (2%) 57/58 
Anaplastic follicular thyroid adenoma (AFTA) 18 3/18 (17%) 15/18 
Radioactive related thyroid carcinoma 51 0/51 (-) 51/51 
Primary gastric cancer 200 0/200 (-) 200/200 
Established cell lines 
ATC cell lines 8  6 / 8 (75%)  2 / 8 
MTC cell lines 2  0 / 2 (-)  2 / 2  
    
 
As controls, we analyzed 20 normal thyroid samples and none of them carried 
TERT promoter mutations. In follicular cell-derived thyroid cancers, TERT 
promoter mutation C228T or C250T was detected. Particularly, mutations were 
also detected in benign thyroid adenoma (FTA) and the pre-malignant tumor 
AFTA, indicating the TERT promoter mutations being present in pre-malignant 
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lesions of the thyroid, too. The two mutations are mutually exclusive. C228T is 
the predominant form of mutations in the cancer types examined in the present 
study, consistent with other observations.  
However, none of 37 medullary thyroid carcinomas (MTCs) carried either 
C228T or C250T mutation, which indicates that the TERT promoter mutation 
occurs only in follicular cell-derived thyroid cancers (Table 5).  
We also got access to a cohort of 51 young PTC patients (age range 19–39 
years; median 31 years) surgically treated at Kyiv City Teaching 
Endocrinological Center, Ukraine, and all these patients had been exposed to 
radioactivity from the accident at the Chernobyl nuclear power station in 
Ukraine in 1986. [122] Unexpectedly, none of the 51 patients carried TERT 
promoter mutations. Thus, this genetic event is not related to radiation in 
thyroid cancer. 
In 200 patients with primary gastric cancer, none of their tumors were found to 
carry TERT promoter mutations. 
 In summary, the frequency of TERT promoter mutations differs among cancers, 
even in different subtypes of the same cancer. Exposure to radioactivity did not 
induce the mutation in thyroid cancer.  
4.2 TERT expression and telomerase activity in FTA and AFTA 
Since the TERT promoter mutation increases TERT transcription, [59] we 
analyzed in vivo TERT mRNA expression and telomerase activity in FTA and 
AFTA samples. All four TERT promoter-carrying samples were observed to 
express TERT mRNA and telomerase activity. For comparison, we further 
analyzed TERT mRNA expression in 7 FTAs and 11AFTAs without TERT 
promoter mutations. Only 1 of these 7 FTAs and 2 of 11 AFTAs expressed 
TERT mRNA. Altogether, there was a highly significant difference in TERT 
expression between C228T-positive and negative tumors.  
4.3 TERT promoter mutations and telomere length 
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Very short telomere is a strong trigger for telomerase activation during cellular 
immortalization. We thus sought to determine whether there was an association 
between TERT promoter mutations and telomere length. In PTC patients, 
telomere length was significantly shorter in patients with TERT promoter 
mutations (0.873 ± 0.45) compared to patients without mutations (1.569 ± 0.627) 
(P < 0.0001) (Figure 5). Because mutations occurred in elderly PTC patients, and 
telomere shortened with age, we further determined the relationship between 
telomere length and age in these patients. The Pearson correlation analysis 
demonstrated that telomere length in PTC cancer cells was independent of 
patients’ age. 
                                             
  
 
 
 
 
 
 
 
 
 
 
 
We also determined the mean telomere length in all FTA and AFTA specimens 
and the results showed that telomere length varied substantially. The C228T 
mutation-positive tumors tended to have shorter telomere compared to the 
negative ones, but the difference was not statistically significant. In addition, 
there was no correlation between patients’ age and telomere length in these 
tumor tissues, either. 
Figure 5. Association of TERT promoter mutations with age and shorter 
telomere in PTC patients. (a) Significantly shorter telomere in PTC patients 
with the TERT promoter mutation (mut) compared with the wild-type (wt) 
carriers. Bars: s.d. (b) Significantly shorter telomere in PTC tumors with the 
TERT promoter mutation stratified by age >45 years. Bars: s.d. (c) Age-
independent telomere length in PTC tumors. Open circles represent telomere 
length in 13 TERT promoter mut-carrying tumors and filled circles represent wt 
cases. 
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4.4 TERT promoter mutations and other gene mutations  
 
4.4.1 TERT promoter mutations are not associated with BRAF mutations in 
PTC  
BRAF mutations are the most common genetic event in PTC with a frequency of 
30 – 70%. [104] To explore whether there is a relationship between these two 
events, we screened the presence of BRAFV600E mutations in PTC patients. We 
identified 32 BRAFV600E positive tumors in 51 PTC patients, but no association 
between these BRAFV600E and TERT promoter mutations were observed. 
 
4.4.2 TERT promoter and NRAS gene mutations in AFTA 
Activating RAS gene mutations are known to occur in both FTA and AFTA. We 
further screened all 18 AFTAs and the C228T-positive FTA for mutations at 
codons 12, 13 and 61 of the HRAS, KRAS and NRAS genes. All 19 tumors 
carried wild type HRAS and KRAS genes. In contrast, five of them were shown 
to have an NRAS missense mutation at codon 61. Three of the NRAS mutated 
cases (1 FTA and 2 AFTA) were positive for C228T. There was a significant 
difference in the presence of the C228T mutation between tumors with and 
without NRAS mutations (P = 0.016). 
 
4.5 TERT promoter mutations and patients’ age 
 
TERT promoter mutations were more common in older age. In the 51 PTCs, all 
the 13 mutation-carrying patients were older than 49 years, and no mutations 
were found in patients <45 years old. The mutation frequency was 52% (13/25) 
in PTC patients >45 years. Thus, the age difference was highly significant 
between patients with and without the TERT promoter mutation (P < 0.0001). 
 
In FTC patients, one of eight TERT promoter mutation-positive FTC patients 
was 31 years old and the remaining were >45 years. The age range was 31 – 83 
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years (median 69 years) and 17 – 77 years (median 54 years) for FTC patients 
with and without TERT promoter mutations, respectively, and this difference 
reached a statistically significant level (P = 0.05).  
 
In the 58 FTA and 18 AFTA patients, all 4 patients with a TERT promoter 
mutation were ≥45 years old at diagnosis. In contrast, none of 28 patients with 
age <45 carried the mutation. However, a statistical analysis did not show a 
significant difference (<45 vs. ≥45, Fisher exact test, P = 0.29), likely due to the 
small number of patients with TERT promoter mutations. 
 
Furthermore, we sequenced the cohort of 51 young PTC patients (age range 19 
– 39 years old; median 31 years) surgically treated at Kyiv City Teaching 
Endocrinological Center, Ukraine, and all these patients had been exposed to 
radioactivity from the accident at the Chernobyl nuclear power station in 
Ukraine in 1986. Consistently, none of these 51 young patients carried the 
TERT promoter mutation in their tumors, which further supported an 
association between senior age and TERT promoter mutations in PTC patients. 
 
4.6 TERT promoter mutations and clinical characteristics  
4.6.1 TERT promoter mutations in aggressive thyroid cancer 
The results from both thyroid cell lines and primary tumors, showed that the 
most aggressive carcinomas had the highest prevalence of  TERT promoter 
mutations in all tumor subtypes (the mutation rates for ATC, PTC, FTC, 
AFTA, and FTA were 50%, 27%, 22%, 17%, and 3%, respectively), indicating 
a link between mutations and progressive diseases.  
 
In FTAs, the only C228T-carrying patient had a recurrence at the scar site three 
years after primary surgery. This patient subsequently developed metastasis and 
died from the disease. A final diagnosis of FTC was confirmed at autopsy. In 
contrast, none of 57 TERT mutation-negative FTA cases progressed into FTC. 
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Taken together, the TERT promoter mutation predominantly occurs in more 
aggressive thyroid cancer and its presence in pre-malignant lesions of the thyroid 
may be a risk factor for malignant transformation. 
 
4.6.2 TERT promoter mutations and patients’ prognosis 
 
Since there is a link between TERT promoter mutations and aggressive tumors, we 
asked whether these genetic events predicted outcomes in thyroid cancer. 
 
In ATC patients, there was no difference in tumor size and metastasis between 
the TERT promoter mutation-positive and -negative tumors. These patients all 
died of the disease except one. The patients with the mutation tended to have a 
shorter overall survival (OS) than those with a wild-type TERT promoter. 
 
In PTC patients, the presence of the TERT promoter mutation was strongly 
associated with metastasis (7/11 in mutated vs. 3/25 in wild type, Fisher exact 
test, P = 0.028). Univariate analyses showed that TERT promoter mutations 
and age >45 years, were significantly associated with shorter overall survival 
(OS) (Figure 6). On multivariate analysis, age >45 years remained significantly 
associated with shorter OS. However, an opposite result was obtained for 
disease-specific survival (DSS). Both the presence of the TERT promoter 
mutation and age >45 years were significantly correlated with a shorter DSS in 
PTC patients using univariate analysis (P < 0.0001 and = 0.015 for mutated 
TERT promoter and age >45, respectively), whereas the former, but not 
age>45 years independently predicted a shorter DSS, in multivariate analysis. 
(P = 0.021 and 0.882 for the TERT mutated promoter and age >45 years, 
respectively) (Figure 6). 
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Figure 6. The relationship between patients’ survival and TERT promoter 
mutation/age in papillary thyroid carcinoma (PTC). Kaplan–Meier plots 
showing overall survival (left) and disease-related survival (right) 
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In FTC patients, the TERT promoter mutation and age >45 years were both 
associated with inferior OS (P = 0.038 and 0.003, respectively). Borderline 
significantly worse DSS was associated with the TERT promoter mutation (P = 
0.058) and age >45 years was significantly associated with a shorter DSS in 
univariate analysis (P = 0.019). However, both of them were unable to predict 
DSS independently, as revealed by the multivariate analysis. 
 
 In primary gastric cancer, there were no TERT promoter mutations found in 200 
patients, and these genetic alterations were not involved in telomerase activation 
occurring in gastric cancer. 
 
4.7 TERT and oncogenic factor COX2 expression in cancer 
 
4.7.1 TERT depletion leads to up-regulation of COX2 expression in cancer 
cells 
 
COX2 was found to activate TERT transcription in our previous study. [123] 
To see whether TERT affects COX2 expression, we knocked down TERT 
expression in gastric and cervical cancer cells using siRNA oligos specifically 
targeting TERT mRNA. 
 
Following TERT depletion, the expression of COX2 was up-regulated at both 
mRNA and protein levels, as determined using qPCR and western blot, 
respectively. TERT depletion-mediated COX2 induction occurred already at 24 
hrs, and lasted for the whole observation period (96 hrs), suggesting a 
constitutive rather than transient up-regulation of COX2 expression (Figure 7). 
 
To determine whether TERT knocking down specifically up-regulates COX2 
expression, we determined COX1 expression, the isoform of COX2 in the 
same sets of cDNA, and no significant change in COX1 mRNA level was 
observed. When we transfected control and TERT siRNA into normal human 
fibroblasts and the osteosarcoma cell line U2OS lacking TERT expression and 
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telomerase activity, COX2 expression did not increase, which indicates a 
specific effect of TERT depletion on COX2 induction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
4.7.2 The COX2 promoter is activated in TERT-depleted cells 
 
To probe the mechanism behind the COX2 induction mediated by TERT 
knocking down, we transfected BGC-823 cells with a reporter construct 
harboring a core COX2 promoter sequence (−327 - +59). The COX2 promoter 
activity was significantly higher in TERT-depleted BGC-823 cells compared to 
that in the cells with the control siRNA. So the induction of COX2 expression 
by TERT depletion occurs at the transcriptional level. 
 
4.7.3 p38 MAPK is involved in COX2 induction by TERT depletion 
 
The p38 MAPK signaling pathway plays an important role in the regulation of 
COX2 transcription [124-128], while telomerase inhibition was previously 
shown to activate p38 MAPK in leukemic cells. [129] Thus we wanted to 
probe if this regulatory loop was present in cancer cells. We compared the 
phosphorylated p38 MAPK at Thr180/Tyr182 (p-p38) between control and 
TERT siRNA-treated BGC-823 and HeLa cells, and the immunoblotting 
Figure 7. TERT knocking down-mediated COX2 up-regulation. qPCR and 
immunoblotting analyses were performed to assess COX2 expression at both 
mRNA and protein levels in cell lines 72 h post-transfection of TERT siRNA. 
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results showed a substantial increase in p-p38 levels in TERT knocked-down 
cells (Figure 8). 
 
We further tested whether inhibiting the p38 MAPK activity was capable of 
blocking the up-regulation of COX2 expression following TERT knocking 
down. Indeed, the specific p38 MAPK inhibitor SB203580 abolished the 
stimulatory effect of TERT depletion on COX2 expression in both BGC-823 
and HeLa cells (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
4.7.4 The TERT depletion-mediated COX2 up-regulation is independent 
of telomere length 
 
TERT is the catalytic component of the telomerase complex and its canonical 
function is telomere elongation. We thus asked whether TERT inhibition led to 
telomere shortening, thereby triggering p38 phosphorylation and COX2 up-
regulation. No detectable changes in telomere length were observed in control 
and TERT siRNA treated BGC-823 cells, as determined using Q-FISH. The 
results suggest a telomere lengthening-independent effect of TERT on the 
stimulation of p38 MAPK activation and COX2 expression. 
 
4.7.5 Synergistic apoptosis induction by inhibiting both TERT and COX2  
 
Figure 8. p-p38 expression increased after TERT depletion in cell lines and the 
TERT depletion-mediated COX2 up-regulation was abolished by inhibiting p38 
MAPK activity. 
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In vitro studies  
As COX2 promotes cancer cell survival and/or proliferation, we wanted to 
know whether COX2 inhibitors facilitated the anti-cancer effect of 
telomerase/TERT inhibition. BGC-823 cells were transfected with TERT 
siRNA followed by immediate treatment with celecoxib, a specific COX2 
inhibitor. Compared with control cells, TERT depletion or celecoxib treatment 
at 50 µM alone did not lead to significant changes in the cell number, however, 
when combined together, there was a robust decrease of viable cells (Figure 9). 
Flow cytometry analysis of DNA stained with PI showed the constant result: 
significant apoptotic death of TERT depleted cells in the presence of celecoxib 
(Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In vivo observations 
To determine whether the above results obtained from in vitro studies could be 
reproduced in an in vivo setting, we further performed the experiments with the 
xenograft model of human gastric cancer in nude mice. BGC-823 cells were 
infected with either an empty lenti-viral vector or one generating TERT siRNA 
Figure 9. TERT knocking down and celecoxib exposure synergistically 
induce apoptosis of BGC-823 cells in culture. Left: Significant decrease 
of viable cells in TERT knocked-down cells treated with celecoxib. Right: 
Synergistic induction of apoptosis in BGC-823 cells treated with the 
combination of TERT siRNA and celecoxib. Abbreviations: C=Control; 
h=hTERT.
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to stably knockdown TERT expression, and cells were then subcutaneously 
injected into the back of nude mice following 1 week selection with 
puromycin. Both BGC-823 control and TERT siRNA cells formed tumors with 
comparable size and weight in nude mice. Tumor size and weight were 
significantly diminished in BGC-823 TERT siRNA cell bearing mice fed with 
celecoxib (Figure 10). Furthermore, compared with other three groups, cellular 
constituents in tumors were much less dense in the group mice bearing TERT-
depleted cells and fed with celecoxib. 
 
 
 
 
 
 
 
 
 
 
Figure 10. TERT-depletion and celecoxib treatment synergistically 
inhibit in vivo tumor growth. Control and TERT-depleted BGC-823 gastric 
cancer cells were subcutaneously injected into the back of nude mice 
and mice then fed with and without celecoxib. Tumor size (left panel) 
and weight (right panel) in mice with different treatments were measured after 
3 weeks. Abbreviations: C=Control; h=hTERT. 
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5 DISCUSSION 
 
Recent studies have revealed somatic TERT promoter mutations in different 
types of human malignancies. In our study, we determined TERT promoter 
mutations in thyroid cancer-derived cell lines and primary thyroid cancer 
specimens, pre-malignant thyroid tumors and primary gastric cancer. We 
observed different mutation frequencies in different types of thyroid cancer. 
The highest mutation rate occurred in anaplastic thyroid carcinoma (ATC) cell 
lines, which was 75%. In the primary tumors, ATC exhibited the most frequent 
mutations (50%), while differentiated follicular cell derived tumors, PTCs and 
FTCs, have a mutation rate of above 20%. However, in C cell-derived MTC 
tumors or cell lines, no mutations were found, which indicated a tumor type-
specific TERT promoter mutation. 
 
Age is an important factor in the mutation event. In both PTC and FTC 
patients, older age is associated with a higher mutation rate. In the most 
aggressive ATC, which had the highest mutation rate, all patients were above 
50 at diagnosis. In contrast, 51 PTC patients from the Ukraine Chernobyl 
disaster were all younger than 40 years old, and no mutations were found in 
this cohort of patients, although PTC has a mutation rate over 20% in the 
Swedish patient group.  
 
We found that in PTC, the TERT promoter mutation-positive patients had 
shorter telomere. Since the mutation occurred in older patients and telomere 
length shortened with age, we compared patients’ age with their telomere 
length in tumors. We didn’t find any association between age and telomere 
length. Taken together, TERT promoter mutations are associated with shorter 
telomere length in cancer cells. 
 
We provide the following model to explain why TERT promoter mutations 
occur in old patients with thyroid cancer. Thyroid epithelial cells from later age 
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possess relative shorter telomeres due to their progressive erosion, and when 
oncogenic events drive active proliferation of these thyroid cells with 
diminished telomerase activity, excessive loss of telomeres leads to telomere 
dysfunction or even telomere crisis. Too short telomeres or telomere crisis 
triggers genomic instability and force cells to undergo telomerase activation, 
via TERT promoter mutations. In contrast, young individuals’ thyroid 
epithelial cells have longer telomeres coupled with telomerase proficiency, and 
in such cases, their telomeres are likely long enough to avoid telomere crisis 
and telomerase may be up-regulated via other pathways rather than the TERT 
promoter mutation. However, TERT promoter mutations are not always 
present in older patients with other tumors. Medulloblastoma has a TERT 
promoter mutation frequency over 20%, whereas it is the most common 
malignant brain tumor of childhood. [68] 
 
When analyzing an association between the mutation status and prognosis, we 
found that ATC patients with TERT promoter mutations tended to survive 
shorter compared with those without the mutation. In PTC patients, the 
presence of TERT promoter mutations was highly correlated with metastasis, 
and was a strong and independent factor to predict DSS. Age >45 years were 
correlated with worse OS, but did not predict DSS independently. We also 
found that FTC patients carrying the TERT promoter mutation exhibited 
substantially shorter OS and DSS. Collectively, the presence of the TERT 
promoter mutation may define a fraction of thyroid cancer patients with 
progressive disease and unfavorable outcomes. 
 
Although TERT expression and telomerase activation is present in up to 90% 
of human malignancies, it is currently unclear how early this occurs in 
carcinogenesis. We have found one TERT promoter mutation in 58 FTA 
patients and 3 in 18 AFTA patients, respectively. FTA is a benign thyroid 
tumor and AFTA has an uncertain malignant potential. Both belong to pre-
malignant lesions of the thyroid. None of the 57 mutation negative patients had 
progressed into FTC, whereas one of the mutation-positive patient who initially 
presented without features of AFTA or FTC, developed a scar recurrence with 
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histopathological features of AFTA and suggestive of FTC followed by 
recurrent metastatic FTC. This finding indicates that TERT promoter mutation 
may be a risk factor for FTA transforming into FTC. TERT promoter 
mutations were also found in cirrhotic preneoplastic macronodules and 
hepatocellular adenomas with malignant transformation. [66] Collectively, 
TERT promoter mutations occur early in the pre-malignant stage of 
oncogenesis, and the presence of TERT promoter mutations may predicate a 
future development of a full malignancy. 
 
In the 200 primary gastric tumors that we analyzed, no TERT promoter 
mutations were found. There was also the absence of the mutation in breast 
cancer, prostate cancer or acute myeloid leukemia. [68] Despite so, there is still 
telomerase activity in these malignancies, and thus alternative mechanisms 
must account for their telomerase activation. 
 
Telomerase has multiple activities in addition to its telomere-lengthening 
function. [54, 55, 58, 68] When TERT is inhibited, the effect and expression of 
proliferation- and survival-related factors are in general attenuated. However, 
our study unexpectedly showed that TERT knocking down led to a significant 
increase in COX2 expression. Since COX2 acts as an important oncogenic 
factor by promoting cell proliferation and/or survival, it’s thus of importance to 
define the functional significance of COX2 up-regulation in TERT-depleted 
cancer cells. We evaluated both the in vitro and in vivo effects of TERT 
depletion and COX2 inhibition alone or in combination on BGC-823 cells. 
Neither TERT knocking down nor celecoxib treatment alone induced cell 
apoptosis in culture, whereas the combined treatment led to a dramatic 
decrease in cell numbers. This was also the case in the mouse xenograft model 
of human gastric cancer, which indicates their in vivo synergistic effect, too.  
 
A number of previous studies have shown that telomerase or TERT inhibition 
induces apoptosis of certain cancer cells that occurs rapidly before telomeres 
become shorter. [130, 131] However, TERT depletion seemed not to inhibit 
proliferation and survival of BGC-823 cells at least within a 96-h period 
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examined. Telomerase inhibition leads to telomere shortening in cancer, which 
takes a period for cellular telomere become dysfunctional. This time lag might 
significantly affect the efficacy of telomerase inhibition and limits its clinical 
application. [19, 132-134] Our findings should help overcome these 
disadvantages by combining telomerase and COX2 inhibitors together and may 
have therapeutic implications in a telomerase-based anticancer strategy. 
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6 SUMMARY & CONCLUSIONS 
1. TERT promoter mutations occur in pre-malignant thyroid lesions and are 
strongly associated with increased TERT mRNA expression and 
telomerase activity. This indicates that the mutation is an early genetic 
event in carcinogenesis and that telomerase can be activated in the initial 
stage of cancer formation. 
2. TERT promoter mutations are identified in follicular thyroid cell-derived 
carcinomas and associated with aggressive disease, and poor outcomes. 
3. TERT promoter mutations are absent in C cell-derived medullary thyroid 
cancer and gastric cancer, suggesting that these genetic events are not 
responsible for telomerase activation in both malignancies. 
4. TERT inhibition-mediated COX2 induction may protect cancer cells 
from apoptosis. Thus simultaneously targeting TERT and COX2 has 
synergistic killing effects on cancer cells, which may have implications 
in rational development of a telomerase-based anti-cancer strategy. 
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